Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

• A new vaccine candidate VLA84 to prevent CDI has been tested in a Phase I trial. • VLA84 was safe and well tolerated in healthy adult and healthy elderly volunteers. • VLA84 was highly immunogenic in adults and elderly. • IgG antibodies persisted at least 6 months after last immunization. • Functi...
Ausführliche Beschreibung

• A new vaccine candidate VLA84 to prevent CDI has been tested in a Phase I trial. • VLA84 was safe and well tolerated in healthy adult and healthy elderly volunteers. • VLA84 was highly immunogenic in adults and elderly. • IgG antibodies persisted at least 6 months after last immunization. • Functionality of IgG antibodies was shown in a T84 toxin neutralization assay. Ausführliche Beschreibung